for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
Pamela Munster, MD (ucsf)
Photo of Pamela Munster
Pamela Munster



This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.

Official Title

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176


This is a first-in-human, Phase 1/2 multicenter, open-label, dose escalation and expansion study of AO-176 in patients with solid tumors. Part A of this study will examine escalating repeat doses of AO-176 monotherapy in patients with select advanced solid tumors (epithelial ovarian carcinoma, including primary peritoneal and fallopian tube carcinoma, squamous cell carcinoma of head and neck, endometrial carcinoma, castration resistant prostate cancer, non-small cell lung adenocarcinoma, papillary thyroid carcinoma, pleural or peritoneal malignant mesothelioma and gastroesophageal adenocarcinoma) for which standard therapy proven to provide clinical benefit does not exist or is no longer effective.

The study utilizes a classic 3+3 design, with enrollment of 3 patients per cohort and expansion of the cohort in the event of a dose-limiting toxicity (DLT).

Once the maximum-tolerated dose (MTD)/recommended phase 2 dose (RP2D) has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.


Solid Tumor CD47 AO-176 Immunotherapy AO-176 Dose Escalation AO-176 Dose Expansion


You can join if…

Open to people ages 18 years and up

  1. Select advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist, or is no longer effective
  2. Measurable disease
  3. ECOG status 0-1
  4. Resolution of prior-therapy-related adverse effects
  5. Minimum of 3 weeks or 5 half-lives since last dose of cancer therapy

You CAN'T join if...

  1. Previous hypersensitivity reaction to treatment with another monoclonal antibody
  2. Prior treatment with a checkpoint inhibitor (anti-PD-1, PD-L1, CTLA-4 etc.) within 4 weeks
  3. Prior treatment with a CD47-targeted therapy
  4. Prior organ or stem cell transplant


  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States
  • University of Southern California accepting new patients
    Los Angeles California 90033 United States

Lead Scientist at UC Health

  • Pamela Munster, MD (ucsf)
    Professor, Medicine. Authored (or co-authored) 124 research publications.


accepting new patients
Start Date
Completion Date
Arch Oncology
Arch Oncology website
Phase 1/2
Study Type
Last Updated